@adamfeuerstein 6-month FEV1 data from VX-809 combo ph3 will impress and prove those who were skeptical based on '56 day' data WRONG.avidresearch (@avidresearch) January 2, 2014
@adamfeuerstein AMGN buys UCBSan (@LukatonMateo) January 5, 2014
Buy signals have not lasted more than two months, so far.
Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!